Analyst Price Target is $8.50
▲ +143.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pieris Pharmaceuticals in the last 3 months. The average price target is $8.50, with a high forecast of $9.00 and a low forecast of $8.00. The average price target represents a 143.55% upside from the last price of $3.49.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Pieris Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.